Literature DB >> 30111550

Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease.

Jeeyun Ahn1, Jee-Young Lee2, Tae Wan Kim2, Eun Jin Yoon1, Sohee Oh1, Yu Kyeong Kim1, Jong-Min Kim1, Se Joon Woo1, Ki Woong Kim1, Beomseok Jeon1.   

Abstract

OBJECTIVE: To analyze the relationship between retinal thinning and nigral dopaminergic loss in de novo Parkinson disease (PD).
METHODS: Forty-nine patients with PD and 54 age-matched controls were analyzed. Ophthalmologic examination and macula optical coherence tomography scans were performed with additional microperimetry, N-(3-[18F]fluoropropyl)-2-carbomethoxy-3-(4-iodophenyl) nortropane PET, and 3T MRI scans were done in patients with PD only. Retinal layer thickness and volume were measured in subfields of the 1-, 2.22-, and 3.45-mm Early Treatment of Diabetic Retinopathy Study circle and compared in patients with PD and controls. Correlation of inner retinal layer thinning with microperimetric response was examined in patients with PD, and the relationships between retinal layer thickness and dopamine transporter densities in the ipsilateral caudate, anterior and posterior putamen, and substantia nigra were analyzed.
RESULTS: Retinal layer thinning was observed in the temporal and inferior 2.22-mm sectors (false discovery rate-adjusted p < 0.05) of drug-naive patients with PD, particularly the inner plexiform and ganglion cell layers. The thickness of these layers in the inferior 2.22-mm sector showed a negative correlation with the Hoehn and Yahr stage (p = 0.032 and 0.014, respectively). There was positive correlation between macular sensitivity and retinal layer thickness in all 3.45-mm sectors, the superior 2.22-mm sector, and 1-mm circle (p < 0.05 for all). There was an association between retinal thinning and dopaminergic loss in the left substantia nigra (false discovery rate-adjusted p < 0.001).
CONCLUSION: Retinal thinning is present in the early stages of PD, correlates with disease severity, and may be linked to nigral dopaminergic degeneration. Retinal imaging may be useful for detection of pathologic changes occurring in early PD.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30111550     DOI: 10.1212/WNL.0000000000006157

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019.

Authors: 
Journal:  Neuroophthalmology       Date:  2019-06-07

2.  Macular ganglion-cell-complex layer thinning and optic nerve integrity in drug-naïve Parkinson's disease.

Authors:  Jee-Young Lee; Jeeyun Ahn; Eun Jin Yoon; Sohee Oh; Yu Kyeong Kim; Beomseok Jeon
Journal:  J Neural Transm (Vienna)       Date:  2019-10-19       Impact factor: 3.575

3.  Diagnostic assessment of glaucoma and non-glaucomatous optic neuropathies via optical texture analysis of the retinal nerve fibre layer.

Authors:  Christopher Kai Shun Leung; Alexander Ka Ngai Lam; Robert Neal Weinreb; David F Garway-Heath; Marco Yu; Philip Yawen Guo; Vivian Sheung Man Chiu; Kelvin Ho Nam Wan; Mandy Wong; Ken Zhongheng Wu; Carol Yim Lui Cheung; Chen Lin; Carmen Kar Mun Chan; Noel Ching Yan Chan; Ka Wai Kam; Gilda Wing Ki Lai
Journal:  Nat Biomed Eng       Date:  2022-01-06       Impact factor: 25.671

Review 4.  Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease.

Authors:  Jee-Young Lee; Antonio Martin-Bastida; Ane Murueta-Goyena; Iñigo Gabilondo; Nicolás Cuenca; Paola Piccini; Beomseok Jeon
Journal:  Nat Rev Neurol       Date:  2022-02-17       Impact factor: 44.711

Review 5.  Past, present and future role of retinal imaging in neurodegenerative disease.

Authors:  Amir H Kashani; Samuel Asanad; Jane W Chan; Maxwell B Singer; Jiong Zhang; Mona Sharifi; Maziyar M Khansari; Farzan Abdolahi; Yonggang Shi; Alessandro Biffi; Helena Chui; John M Ringman
Journal:  Prog Retin Eye Res       Date:  2021-01-15       Impact factor: 19.704

Review 6.  Rhodopsin: A Potential Biomarker for Neurodegenerative Diseases.

Authors:  Cameron Lenahan; Rajvee Sanghavi; Lei Huang; John H Zhang
Journal:  Front Neurosci       Date:  2020-04-15       Impact factor: 4.677

7.  Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases.

Authors:  Ane Murueta-Goyena; Rocío Del Pino; Paula Reyero; Marta Galdós; Begoña Arana; Olaia Lucas-Jiménez; Marian Acera; Beatriz Tijero; Naroa Ibarretxe-Bilbao; Natalia Ojeda; Javier Peña; Jesús Cortés; Juan Carlos Gómez-Esteban; Iñigo Gabilondo
Journal:  Mov Disord       Date:  2019-05-28       Impact factor: 10.338

Review 8.  Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson's Disease.

Authors:  Ane Murueta-Goyena; Ane Andikoetxea; Juan Carlos Gómez-Esteban; Iñigo Gabilondo
Journal:  Front Pharmacol       Date:  2019-10-30       Impact factor: 5.810

Review 9.  Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder.

Authors:  Mitchell G Miglis; Charles H Adler; Elena Antelmi; Dario Arnaldi; Luca Baldelli; Bradley F Boeve; Matteo Cesari; Irene Dall'Antonia; Nico J Diederich; Kathrin Doppler; Petr Dušek; Raffaele Ferri; Jean-François Gagnon; Ziv Gan-Or; Wiebke Hermann; Birgit Högl; Michele T Hu; Alex Iranzo; Annette Janzen; Anastasia Kuzkina; Jee-Young Lee; Klaus L Leenders; Simon J G Lewis; Claudio Liguori; Jun Liu; Christine Lo; Kaylena A Ehgoetz Martens; Jiri Nepozitek; Giuseppe Plazzi; Federica Provini; Monica Puligheddu; Michal Rolinski; Jan Rusz; Ambra Stefani; Rebekah L S Summers; Dallah Yoo; Jennifer Zitser; Wolfgang H Oertel
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 44.182

10.  Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology.

Authors:  Jeffrey M Boertien; Sygrid van der Zee; Asterios Chrysou; Marleen J J Gerritsen; Nomdo M Jansonius; Jacoba M Spikman; Teus van Laar
Journal:  BMC Neurol       Date:  2020-06-13       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.